

Solutions

2.1

- 2–5 % ✓.

2.2

- CYP2C19 poor metaboliser (no prodrug activation).

2.3

- HLA-B*57:01 (hypersensitivity).

3.1

- 2–4 % after one; ~10 % after two.
- Additional affected relatives shift the family's liability distribution right: more siblings cross the threshold.
- Folic acid 4 mg/day pre-conception and first trimester for every subsequent pregnancy – cheap, safe, and risk-independent.

3.2

- CYP2C19: prevents ineffective antiplatelet therapy (stent thrombosis); TPMT: prevents severe myelosuppression; HLA-B*57:01: prevents abacavir hypersensitivity.
- Each is a screening test with a prescription attached.
- Principle: the result guides the drug and dose – a dosing instruction, not a disease diagnosis.